As someone pointed out elsewhere, not only is leronlimab "competing" against a placebo in the S/C trials, it is "competing" against SOC.

That raises the bar a little bit further taking these articles into account.

I feel if leronlimab is able to show statistical (not clinical) significance, then no one can deny that it is effective and safe.